Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 19/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 19/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 19/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15818305 | 1.00 | PIM1 (0.45) | PIM1PIM3PIM2KDM4EALDH1A1 | |
| SCHEMBL17272981 | 1.00 | PIM1 (0.45) | PIM1PIM3PIM2KDM4EALDH1A1 | |
| SCHEMBL17272982 | 1.00 | PIM1 (0.45) | PIM1PIM3PIM2KDM4EALDH1A1 | |
| SCHEMBL15817952 | 0.88 | PIM1 (0.44) | PIM1PIM3PIM2 | |
| SCHEMBL15817954 | 0.88 | PIM1 (0.44) | PIM1PIM3PIM2 | |
| SCHEMBL15589000 | 0.87 | PIM1 (0.41) | PIM1PIM3PIM2 | |
| SCHEMBL15589065 | 0.87 | PIM1 (0.41) | PIM1PIM3PIM2 | |
| SCHEMBL15589067 | 0.87 | PIM1 (0.41) | PIM1PIM3PIM2 | |
| SCHEMBL15588999 | 0.87 | PIM1 (0.41) | PIM1PIM3PIM2 | |
| SCHEMBL15557301 | 0.85 | PIM1 (0.49) | PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935270-A1 | ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS | Novartis AG (CH) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014099880-A1 | ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS | NOVARTIS AG (CH) | 2014-06-26 | — | — | WO | disclosed |